Clinical Trial Evaluates Oral Orforglipron Against Semaglutide
A new once-daily tablet, orforglipron, outperformed oral semaglutide in a phase 3 clinical trial. Researchers evaluated this new receptor…
-
-
Semaglutide Approval Links to Surge in Poison Control Calls
National poison control centers reported a significant increase in calls related to glucagon-like peptide-1 receptor agonists. This surge followed…
-
Clinical Management of Wegovy Storage Protocols
Proper storage of injectable semaglutide products directly affects medication strength and patient safety. Wegovy, a glucagon-like peptide-1 receptor agonist,…
-
Vivani’s Semaglutide Implant Aims to Solve GLP-1 Treatment Discontinuation
Sustaining long-term weight loss with GLP-1 medications is a tough challenge. Patients often stop treatment because of side effects,…
-
National Survey Identifies Significant Growth in Receptor Agonist Utilization for Weight Management
Recent national survey data shows that 11 percent of adults currently use a glucagon-like peptide-1 receptor agonist medication for…
-
Nestle Reformulates Food Products for Consumers Using GLP-1 Medications
Nestle is changing some product formulations to meet the taste needs of patients using GLP-1 receptor agonists. Marketing chief…
-
Semaglutide and Metabolism: What You Should Know
Semaglutide is a widely prescribed medication for obesity and type 2 diabetes. The drug is the active ingredient in…
-
Rybelsus Oral Tablets Expand GLP-1 Access for Type 2 Diabetes Patients
The oral form of semaglutide is the first widely available glucagon-like peptide-1 receptor agonist that does not require an…
-
GLP-3 Versus GLP-1: A Clinical Comparison for Weight Loss Management
Clinicians and patients often come across the term GLP-3 when discussing new obesity treatments. This term does not have…
-
Novo Nordisk Oral Wegovy Strengthens Obesity Market
Novo Nordisk recorded over three million prescriptions for oral Wegovy within five months of its availability. Financial analysts gave…
